ATIR101: Ph III CR-AIR-009 started

Kiadis began the open-label, international Phase III CR-AIR-009 trial to compare T cell-depleted HSCT followed by IV ATIR101 vs. T cell replete HSCT followed by high-dose cyclophosphamide in about 195...